RXi Pharmaceuticals Corp., a clinical-stage biotechnology company based in Marlborough, has been granted a Chinese patent for the composition and methods of use for compounds that may be used to treat dermal scarring, the company announced Monday.
A three-year contract has been ratified by 198 nurses at the Marlborough Hospital, representing the last Massachusetts Nurses Association-represented hospital to settle a contract, the association announced Wednesday.
Nuclea Biotechnologies, Inc., based in Pittsfield but with operations in Worcester, has announced that a kit using Carbonic Anhydrase IX has been classified by the Food and Drug Administration (FDA) as a Class I in vitro diagnostic (IVD) device for use on a Ventana Benchmark XT instrument.
Health care workers on Tuesday spoke out in favor of a proposed bill, which proponents say will reduce health care spending while boosting community hospitals, during a legislative hearing before the Joint Committee on Health Care Financing.